Anúncio
Anúncio
IBRX
ImmunityBio, Inc. Common Stock
2.33
USDPatrocinado
+0.09
+4.24%
09 de jan., 15:57 UTC -5
Encerrado
Pós-Mercado
2.35
+0.01
+0.43%
Relatórios de Lucros IBRX
Rácio de surpresa positiva
IBRX separação 22 de 40 últimas estimativas.
55%
Próximo Relatório
Data do Próximo Relatório
02 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$36.70M
/-$0.11
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+14.47%
/+57.14%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+385.96%
/+22.22%
ImmunityBio, Inc. Common Stock earnings per share and revenue
On 04 de nov. de 2025, IBRX reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.11 USD, resulting in a 36.48% surprise. Revenue reached 32.06 milhão, compared to an expected 32.52 milhão, with a -1.40% difference. The market reacted with a +3.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of -0.11 USD, with revenue projected to reach 36.70 milhão USD, implying an aumentar of 57.14% EPS, and aumentar of 14.47% in Revenue from the last quarter.
FAQ
What were ImmunityBio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ImmunityBio, Inc. Common Stock reported EPS of -$0.07, beating estimates by 36.48%, and revenue of $32.06M, -1.4% below expectations.
How did the market react to ImmunityBio, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.37%, changed from $2.08 before the earnings release to $2.15 the day after.
When is ImmunityBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for 02 de mar. de 2026.
What are the forecasts for ImmunityBio, Inc. Common Stock's next earnings report?
Based on 7
analistas, ImmunityBio, Inc. Common Stock is expected to report EPS of -$0.11 and revenue of $36.70M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio